Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck Seeks Antiviral With AiCuris …
by Ann M. Thayer
October 22, 2012
| A version of this story appeared in
Volume 90, Issue 43
Merck & Co. has licensed a portfolio of drug candidates targeting human cytomegalovirus (HCMV) from Germany’s AiCuris, a 2006 spin-off from Bayer HealthCare. Merck will pay AiCuris $144 million up front and up to $436 million in potential milestones. It will also cover development costs. Included in the agreement is letermovir, an oral, late-stage antiviral candidate being tested against HCMV infections in transplant recipients. The agreement marks the first development deal emerging from AiCuris’ anti-infective drug R&D programs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter